Shares of vaccine makers fell on reports that President-elect Donald Trump is expected to nominate Robert F. Kennedy Jr., a ...

Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025Reiterate cash runway into mid-2026; Q3 2024 ending ...

On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...

Respiratory syncytial virus (RSV) caused significant hospitalizations and severe outcomes in adults, especially those aged 75 ...

MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), ...

Veeva Systems (NYSE: VEEV) today announced that leaders from Almirall, AstraZeneca, Bayer AG, BioNTech SE, Glenmark, and GSK ...

GSK plc announced the results of a GSK-sponsored multinational survey designed to raise awareness of challenges that people with gynaecologic cancers may experience. The survey, which was conducted by ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...